The business model of Transgene SA is focused on developing innovative immunotherapies for the treatment of cancer and infectious diseases. As a biotechnology company, Transgene SA utilizes its expertise in viral vector technology to design and manufacture targeted therapies. The company conducts extensive research and clinical trials to validate the efficacy and safety of its treatments. Transgene SA also collaborates with strategic partners and pharmaceutical companies to enhance the development and commercialization of its products. By leveraging its innovative approach and strategic alliances, Transgene SA aims to address unmet medical needs and improve patient outcomes in the field of immunotherapy.

Transgene SA is primarily active in the biotechnology industry. As a leading company in the field, Transgene focuses on developing innovative immunotherapies for treating different types of cancer. By leveraging its expertise in viral vector technology, Transgene aims to provide breakthrough solutions that can enhance the immune system's ability to fight cancer cells effectively. With its strong commitment to research and development, Transgene strives to bring novel therapies to patients, contributing to the advancement of cancer treatment options.

The main competitors of Transgene SA in the market are other biotechnology companies that operate within the same sector, such as BioNTech SE, Cellectis SA, and CRISPR Therapeutics AG. These companies also focus on developing innovative therapies and treatments to address various diseases and medical conditions. However, Transgene SA distinguishes itself by leveraging its proprietary technologies, such as its gene therapy platform and viral vector system, to advance its pipeline of potential treatments. By continuously exploring cutting-edge research and collaborations, Transgene SA aims to establish a strong presence and competitive edge in the biotechnology market.

Transgene SA is a leading biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. Established in 1979, Transgene has a rich history of innovation and scientific expertise. The company has dedicated its efforts to leveraging the power of viruses to deliver therapeutic agents directly into cells, enabling targeted and potent treatments. Transgene has collaborated with renowned partners and successfully advanced multiple programs into clinical trials. With a strong commitment to improving patient outcomes, Transgene SA continues to pave the way in the field of immunotherapy, offering promising prospects for the future of cancer treatments.

Transgene SA, a leading biotechnology company, has achieved significant milestones throughout its history. The company has successfully developed and advanced innovative immunotherapies, focusing on viral vector-based platforms. It has conducted rigorous clinical trials and received regulatory approvals for its potential breakthrough treatments. Transgene SA has forged strategic partnerships with renowned pharmaceutical companies, facilitating the advancement of its product portfolio. The company has also demonstrated its expertise in translational research, presenting promising results and publications in reputable scientific journals. These milestones highlight Transgene SA's commitment to revolutionizing the treatment landscape for various diseases, solidifying its reputation as a key player in the biotech industry.

Transgene SA is primarily present in France, with its headquarters located in Strasbourg. It is a biotechnology company that focuses on designing and developing immunotherapy products to target and treat cancer and infectious diseases. With a strong presence in France, Transgene SA operates globally, collaborating with international research centers, universities, and pharmaceutical companies to advance its innovative treatments. The company's dedication to revolutionizing healthcare extends beyond borders, as it continues to expand its presence and partnerships to bring its cutting-edge therapies to patients worldwide.

Transgene SA is a leading biotechnology company dedicated to revolutionizing the field of immunotherapy. With a strong focus on patient care, Transgene aims to develop innovative treatments for various types of cancer and infectious diseases. The company's core values encompass excellence, integrity, and collaboration, as it strives to deliver breakthrough therapies that significantly impact patients' lives. Transgene's corporate philosophy emphasizes the importance of scientific innovation, while maintaining the highest ethical standards. Through cutting-edge research and strategic partnerships, Transgene SA is committed to advancing the next generation of immunotherapies and bringing hope to patients worldwide.

Analysts currently set an average price target of 1.38 EUR for the Transgene stock (median: 1.38 EUR), implying +90.2 % versus the latest price. The consensus is based on 7 analyst ratings.

Transgene Analyst Price Targets 2026

7 analysts currently rate the Transgene stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Transgene to generate revenue of 10.17 M EUR and earnings per share of -0.14 EUR.

Transgene Analyst Price Targets 2026

The Transgene share (TNG.PA) is listed on 7 stock exchanges, including: Frankfurt (TGNA.F), München (TGNA.MU), London (0OCQ.L), London (0OCQ.L), Paris (TNG.PA).

Transgene SA is a French company specialized in the development and manufacturing of immunoncological therapies. The company's business model focuses on identifying new target molecules that can be used in cancer therapy and developing therapeutics based on this. Transgene conducts research and development mainly in the area of adeno-associated viruses (AAV) and gene editing. The company is organized into four main business areas. The first one is cancer immunotherapy, where Transgene focuses on developing treatment options for solid tumors. This includes research on new strategies to enhance the effectiveness of immunotherapies and overcome resistance. Another business area of Transgene is new therapeutic approaches, where the company works on innovative compounds based on AAV technology. The potential of the AAV platform is used to develop new treatment options for various diseases. Transgene is also active in the gene editing business area. The focus here is on developing effective methods for genome editing technology to treat and potentially cure genetic diseases. Another important area for Transgene is the licensing of technologies and products. The company has already completed several successful partnerships and is developing joint products with various partners. For example, the company cooperates with AstraZeneca in the development of immunotherapies against solid tumors. One of Transgene's most important products is the oncolytic virus TG6002. This vaccine is based on AAV technology and is designed for the treatment of solid tumors. The virus serves as a carrier for delivering tumor cell-destroying agents into the tumor cells. Apoptosis, or programmed cell death, is used to kill the tumor cells. Another important product for Transgene is the drug NG-348. This is an antibody drug conjugate (ADC) developed for the treatment of various types of cancer. It combines an antibody with a drug against tumor cells. Overall, Transgene follows a business model strongly focused on research and development. The company invests significant amounts in research and development to develop innovative solutions for the treatment of cancer and other diseases. Collaboration with other companies is intended to accelerate the market readiness of the products. Transgene aims to strengthen its position as a leading developer of immunoncological therapies and increase the global availability of its products.

The expected revenue of Transgene is 10.17 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Transgene is -16.50 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Transgene is currently -5.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Transgene stock.

The price-to-sales ratio (P/S) of Transgene is currently 8.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Transgene stock.

The Eulerpool Quality Score for Transgene is 1/10.

The ISIN of Transgene is FR0005175080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Transgene is 913048. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Transgene is TNG.PA. The ticker symbol is used to trade Transgene shares on the stock exchange.

Transgene paid dividends every year for the past 0 years.

Transgene is assigned to the 'Health' sector.

The dividends of Transgene are distributed in EUR.